Cargando…

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahu, Ram Kumar, Ruhi, Sakina, Jeppu, Ashok Kumar, Al-Goshae, Husni Ahmed, Syed, Ayesha, Nagdev, Sanjay, Widyowati, Retno, Ekasari, Wiwied, Khan, Jiyauddin, Bhattacharjee, Bedanta, Goyal, Manoj, Bhattacharya, Sankha, Jangde, Rajendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353315/
https://www.ncbi.nlm.nih.gov/pubmed/37469419
http://dx.doi.org/10.3389/fonc.2023.1204722
_version_ 1785074688947388416
author Sahu, Ram Kumar
Ruhi, Sakina
Jeppu, Ashok Kumar
Al-Goshae, Husni Ahmed
Syed, Ayesha
Nagdev, Sanjay
Widyowati, Retno
Ekasari, Wiwied
Khan, Jiyauddin
Bhattacharjee, Bedanta
Goyal, Manoj
Bhattacharya, Sankha
Jangde, Rajendra K.
author_facet Sahu, Ram Kumar
Ruhi, Sakina
Jeppu, Ashok Kumar
Al-Goshae, Husni Ahmed
Syed, Ayesha
Nagdev, Sanjay
Widyowati, Retno
Ekasari, Wiwied
Khan, Jiyauddin
Bhattacharjee, Bedanta
Goyal, Manoj
Bhattacharya, Sankha
Jangde, Rajendra K.
author_sort Sahu, Ram Kumar
collection PubMed
description The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma.
format Online
Article
Text
id pubmed-10353315
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103533152023-07-19 Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies Sahu, Ram Kumar Ruhi, Sakina Jeppu, Ashok Kumar Al-Goshae, Husni Ahmed Syed, Ayesha Nagdev, Sanjay Widyowati, Retno Ekasari, Wiwied Khan, Jiyauddin Bhattacharjee, Bedanta Goyal, Manoj Bhattacharya, Sankha Jangde, Rajendra K. Front Oncol Oncology The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma. Frontiers Media S.A. 2023-07-04 /pmc/articles/PMC10353315/ /pubmed/37469419 http://dx.doi.org/10.3389/fonc.2023.1204722 Text en Copyright © 2023 Sahu, Ruhi, Jeppu, Al-Goshae, Syed, Nagdev, Widyowati, Ekasari, Khan, Bhattacharjee, Goyal, Bhattacharya and Jangde https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Sahu, Ram Kumar
Ruhi, Sakina
Jeppu, Ashok Kumar
Al-Goshae, Husni Ahmed
Syed, Ayesha
Nagdev, Sanjay
Widyowati, Retno
Ekasari, Wiwied
Khan, Jiyauddin
Bhattacharjee, Bedanta
Goyal, Manoj
Bhattacharya, Sankha
Jangde, Rajendra K.
Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title_full Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title_fullStr Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title_full_unstemmed Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title_short Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
title_sort malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353315/
https://www.ncbi.nlm.nih.gov/pubmed/37469419
http://dx.doi.org/10.3389/fonc.2023.1204722
work_keys_str_mv AT sahuramkumar malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT ruhisakina malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT jeppuashokkumar malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT algoshaehusniahmed malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT syedayesha malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT nagdevsanjay malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT widyowatiretno malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT ekasariwiwied malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT khanjiyauddin malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT bhattacharjeebedanta malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT goyalmanoj malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT bhattacharyasankha malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies
AT jangderajendrak malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies